Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
65.9M
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
14.2M
-
Shares change
-
-399K
-
Total reported value, excl. options
-
$31.1M
-
Value change
-
-$1.59M
-
Put/Call ratio
-
0.6
-
Number of buys
-
31
-
Number of sells
-
-40
-
Price
-
$2.19
Significant Holders of Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO) as of Q2 2022
88 filings reported holding CTSO - Cytosorbents Corp - Common Stock, par value $0.001 per share as of Q2 2022.
Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.2M shares
of 65.9M outstanding shares and own 21.58% of the company stock.
Largest 10 shareholders include Skylands Capital, LLC (2.32M shares), AVENIR CORP (2.16M shares), VANGUARD GROUP INC (1.96M shares), Granahan Investment Management, LLC (1.38M shares), Neuberger Berman Group LLC (1.33M shares), Sargent Investment Group, LLC (977K shares), CM Management, LLC (600K shares), MILLENNIUM MANAGEMENT LLC (525K shares), GEODE CAPITAL MANAGEMENT, LLC (368K shares), and ROYCE & ASSOCIATES LP (349K shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.